Etnaaf 120 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Etoricoxib |
| Company | Naafco pharma ltd |
| Also available as |
Title
Etnaaf 120 mg Tablet
Categories
- Pain Relief
- Anti-inflammatory
- Medication
Description
Etnaaf is indicated for the symptomatic relief of Osteoarthritis (OA), Rheumatoid arthritis (RA), Ankylosing spondylitis, acute gouty arthritis, and short-term treatment of moderate pain associated with dental surgery. It is a selective COX-2 inhibitor.
Dosage
Adult and adolescent over 16 years: Osteoarthritis: 30 mg once daily, increased to 60 mg if needed; Rheumatoid arthritis/Ankylosing spondylitis: 90 mg once daily; Acute gouty arthritis: 120 mg once daily for 8 days; Postoperative dental surgery pain: 90 mg once daily, maximum for 3 days.
Pharmacology
Etoricoxib is a potent COX-2 specific inhibitor, decreasing pain and inflammation with reduced potential for GI toxicity and effects on platelet aggregation.
Interaction
- Oral anticoagulants: May increase prothrombin time
- Diuretics, ACE inhibitors and Angiotensin II Antagonists: May reduce the effect of diuretics and other antihypertensive drugs
- Acetylsalicylic Acid: Can be used concomitantly at low doses for cardiovascular prophylaxis
Contradictions
- Hypersensitivity to the active substance or excipients
- Active peptic ulceration or GI bleeding
- Pregnancy and lactation
- Severe hepatic dysfunction
- Renal creatinine clearance <30 ml/min
- Children and adolescents under 16 years of age
- Inflammatory bowel disease
- Congestive heart failure
- Hypertension not adequately controlled
- Established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease
Side Effects
- Palpitation
- Fatigue
- Influenza-like symptoms
- Ecchymosis
- Dry mouth
- Taste disturbance
- Mouth ulcer
- Atrial fibrillation
- Chest pain
- Flushing
- Cough
- Dyspnoea
- Epistaxis
- Anxiety
- Paraesthesia
- Electrolyte disturbance
- Myalgia
- Arthralgia
- Confusion
- Hallucinations
Pregnancy & Lactation
Not recommended in women attempting to conceive, excreted in the milk of lactating rats.
Precautions & Warnings
- Caution in patients at risk of GI complication
- Caution in patients with significant risk factors for cardiovascular events
- May impair renal function
- Exercised caution in patients with a history of cardiac failure and hypertension
- Monitoring of liver function recommended
- Discontinue at first appearance of hypersensitivity
Overdose Effects
Did not result in significant toxicity up to 150 mg/day for 21 days; employ usual supportive measures in case of overdose.
Therapeutic Class
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Storage Conditions
Store below 30°C, protect from light & moisture, keep out of reach of children.
Chemical Structure
- Molecular Formula: C18H15ClN2O2S
- Chemical Structure Image URL: https://medex.com.bd/storage/res/g-res-446-etoricoxib-chemical-structure-nEkDifKyFxQ9fjJEG7TQ.svg
FAQs About Etnaaf 120 mg Tablet
- Duration of effect
- Onset of action
- Pregnancy warnings
- Habit forming
- Breastfeeding warnings
- Safety with alcohol
- Safety to drive
- Effect on kidney function
- Effect on liver function
- Quick Tips